Float Short %

5.27

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.3

EPS Last/This Y

1.07

EPS This/Next Y

1.26

Price

2.24

Target Price

9.17

Analyst Recom

Performance Q

-3.86

Relative Volume

0.33

Beta

0.35

Ticker: AYTU

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	AYTU	2.07	N/A	N/A	0
2025-11-11	AYTU	2.085	N/A	N/A	0
2025-11-12	AYTU	2.08	N/A	N/A	0
2025-11-13	AYTU	2.04	N/A	N/A	0
2025-11-14	AYTU	2.14	N/A	N/A	0
2025-11-17	AYTU	2	N/A	N/A	0
2025-11-18	AYTU	2.01	N/A	N/A	0
2025-11-19	AYTU	2.01	N/A	N/A	0
2025-11-20	AYTU	1.94	N/A	N/A	0
2025-11-21	AYTU	2.05	N/A	N/A	0
2025-11-24	AYTU	2.09	N/A	N/A	0
2025-11-25	AYTU	2.11	N/A	N/A	0
2025-11-26	AYTU	2.12	N/A	N/A	0
2025-12-01	AYTU	2.06	N/A	N/A	0
2025-12-02	AYTU	2.07	N/A	N/A	0
2025-12-03	AYTU	2.1	N/A	N/A	0
2025-12-04	AYTU	2.24	N/A	N/A	0
2025-12-05	AYTU	2.195	N/A	N/A	0
2025-12-08	AYTU	2.27	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	AYTU	2.09	-	-	-1.27
2025-11-11	AYTU	2.10	-	-	-1.27
2025-11-12	AYTU	2.07	-	-	-1.27
2025-11-13	AYTU	2.05	-	-	-1.27
2025-11-14	AYTU	2.14	-	-	-1.27
2025-11-17	AYTU	1.97	-	-	-1.27
2025-11-18	AYTU	2.00	-	-	-1.27
2025-11-19	AYTU	2.00	-	-	-1.27
2025-11-20	AYTU	1.94	-	-	-1.27
2025-11-21	AYTU	2.10	-	-	-1.09
2025-11-24	AYTU	2.07	-	-	-1.09
2025-11-25	AYTU	2.12	-	-	-1.09
2025-11-26	AYTU	2.10	-	-	-1.09
2025-12-01	AYTU	2.10	-	-	-1.09
2025-12-02	AYTU	2.05	-	-	-1.09
2025-12-03	AYTU	2.13	-	-	-1.09
2025-12-04	AYTU	2.19	-	-	-1.09
2025-12-05	AYTU	2.22	-	-	-1.09
2025-12-08	AYTU	2.24	-	-	-1.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	AYTU	5.85	12.90	6.83
2025-11-11	AYTU	9.74	12.90	6.83
2025-11-12	AYTU	9.74	12.90	5.57
2025-11-13	AYTU	9.74	12.90	5.57
2025-11-14	AYTU	9.74	12.90	5.55
2025-11-17	AYTU	9.75	21.50	5.40
2025-11-18	AYTU	9.75	21.50	5.40
2025-11-19	AYTU	9.75	21.50	5.40
2025-11-20	AYTU	9.75	21.50	5.40
2025-11-21	AYTU	9.74	21.50	5.40
2025-11-24	AYTU	9.75	1.87	5.40
2025-11-25	AYTU	9.78	1.87	5.40
2025-11-26	AYTU	9.78	1.87	5.27
2025-12-01	AYTU	9.78	1.68	5.27
2025-12-02	AYTU	9.78	1.68	5.27
2025-12-03	AYTU	9.78	1.68	5.27
2025-12-04	AYTU	9.78	1.68	5.27
2025-12-05	AYTU	9.78	1.68	5.27
2025-12-08	AYTU	9.78	1.70	5.27
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.08

Avg. EPS Est. Current Quarter

-0.73

Avg. EPS Est. Next Quarter

-0.38

Insider Transactions

9.78

Institutional Transactions

1.7

Beta

0.35

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.1

Max Drawdown 5-Year %

-99.5

Target Price

9.17

P/E

Forward P/E

96.01

PEG

P/S

0.36

P/B

0.96

P/Free Cash Flow

EPS

-3.05

Average EPS Est. Cur. Y

-1.09

EPS Next Y. (Est.)

0.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-20.52

Relative Volume

0.33

Return on Equity vs Sector %

-83.3

Return on Equity vs Industry %

-63.8

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.18

EBIT Estimation

Aytu BioPharma, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 82

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

stock quote shares AYTU – Aytu BioPharma, Inc. Stock Price stock today

news today AYTU – Aytu BioPharma, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AYTU – Aytu BioPharma, Inc. yahoo finance google finance

stock history AYTU – Aytu BioPharma, Inc. invest stock market

stock prices AYTU premarket after hours

ticker AYTU fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: AYTU

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y